NCT05415072
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05415072
Title A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries USA | NLD | FRA | ESP | DEU | CHE | AUS

Facility Status City State Zip Country Details
Massachusetts General Hospital Hematology Oncology Boston Massachusetts 02114 United States Details
Columbia University Medical Center- New York Presbyterian Onc Dept New York New York 10032 United States Details
Memorial Sloane Kettering Cancer Center MSKCC New York New York 10065 United States Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Paris 75231 France Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Leiden South Holland 2333 Netherlands Details
Novartis Investigative Site Madrid 28050 Spain Details
Novartis Investigative Site Zurich 8091 Switzerland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field